GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Myeloproliferative neoplasms (MPNs) are a group of blood cancers.
• Accurate subtyping of BCR/ABL1-negative MPNs is crucial for patient management.
• GATA1 expression is a potential biomarker for MPN characterization.

Purpose of the Study:

• To investigate GATA1 expression levels in different subtypes of BCR/ABL1-negative MPNs.
• To assess the correlation of GATA1 expression with MPN subtypes, mutation profiles, and disease progression.

Main Methods:

• Enrolled 49 patients with BCR/ABL1-negative MPNs (PV, ET, prePMF, PMF).
• Analyzed CALR, MPL mutations, and JAK2 V617F allele burden.
• Quantified GATA1 expression using immunohistochemistry on bone marrow biopsies.

Main Results:

• GATA1 expression was significantly lower in overt primary myelofibrosis (PMF) compared to other MPN subtypes.
• No significant difference in GATA1 expression was observed between essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (prePMF).
• GATA1 expression decreased with overt fibrosis and leukemic transformation, independent of JAK2 V617F allele burden or mutation profiles.

Conclusions:

• GATA1 expression is significantly reduced in PMF and declines with disease progression.
• GATA1 may serve as a marker for fibrosis and leukemic transformation in MPNs.
• Larger cohorts and long-term follow-up are necessary to establish the prognostic significance of GATA1 expression in MPNs.